Compare FSBC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBC | PHAR |
|---|---|---|
| Founded | 2002 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.4M | 885.7M |
| IPO Year | 2021 | 2020 |
| Metric | FSBC | PHAR |
|---|---|---|
| Price | $44.47 | $12.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $41.90 | $38.33 |
| AVG Volume (30 Days) | ★ 87.4K | 9.6K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 28.32 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.25 | $10.04 |
| Revenue Next Year | $12.30 | $2.51 |
| P/E Ratio | ★ $50.64 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.26 | $9.54 |
| 52 Week High | $44.99 | $21.34 |
| Indicator | FSBC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 69.91 | 39.90 |
| Support Level | $39.93 | $11.84 |
| Resistance Level | N/A | $13.61 |
| Average True Range (ATR) | 1.06 | 0.47 |
| MACD | 0.17 | 0.08 |
| Stochastic Oscillator | 87.40 | 29.83 |
Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.